Related references
Note: Only part of the references are listed.Bruton's tyrosine kinase inhibition-An emerging therapeutic strategy in immune-mediated dermatological conditions
Pedro Mendes-Bastos et al.
ALLERGY (2022)
CD38-mediated Inhibition of Bruton's Tyrosine Kinase in Macrophages Prevents Endotoxemic Lung Injury
Joseph Farahany et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2022)
The CLL12 trial: ibrutinib vs placebo in treatment-naive, early-stage chronic lymphocytic leukemia
Petra Langerbeins et al.
BLOOD (2022)
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia
Henriette Huber et al.
BLOOD (2022)
Zanubrutinib for treatment-naive and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study
Gavin Cull et al.
BRITISH JOURNAL OF HAEMATOLOGY (2022)
Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring
Caitlin M. Stewart et al.
CLINICAL CANCER RESEARCH (2022)
Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib
Fansheng Ran et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)
Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies
John N. Allan et al.
HAEMATOLOGICA (2022)
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study
Christian Buske et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma
Preetesh Jain et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter Open-Label, Single-Arm, Phase II Trial
Eva Gine et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis
Brian T. Hopkins et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial
Michael L. Wang et al.
LANCET ONCOLOGY (2022)
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia
Jeff P. Sharman et al.
LEUKEMIA (2022)
Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features
Matt Shirley
TARGETED ONCOLOGY (2022)
The Role of Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions
Tadeusz Robak et al.
CANCERS (2022)
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
Constantine S. Tam et al.
BLOOD ADVANCES (2022)
Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma
Haiyan Yang et al.
BLOOD ADVANCES (2022)
BTK inhibition limits B-cell-T-cell interaction through modulation of B-cell metabolism: implications for multiple sclerosis therapy
Rui Li et al.
ACTA NEUROPATHOLOGICA (2022)
Long-term Outcomes for Ibrutinib-Rituximab and Chemoimmunotherapy in CLL: Updated Results of the E1912 Trial
Tait D. Shanafelt et al.
BLOOD (2022)
Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study
Yuqin Song et al.
BLOOD (2022)
Two-year outcomes of tirabrutinib monotherapy in Waldenstrom's macroglobulinemia
Naohiro Sekiguchi et al.
CANCER SCIENCE (2022)
Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase
Burcu Aslan et al.
HAEMATOLOGICA (2022)
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia
Jorge J. Castillo et al.
LEUKEMIA (2022)
Discovery of Reversible Covalent Bruton's Tyrosine Kinase InhibitorsPRN473 and PRN1008 (Rilzabrutinib)
Timothy D. Owens et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia
David J. Kuter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma
Michael L. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
BTK Inhibitors Impair Platelet-Mediated Antifungal Activity
Vincenzo Nasillo et al.
CELLS (2022)
Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma
Tycel Phillips et al.
BLOOD ADVANCES (2022)
Ventricular arrhythmias and sudden death events following acalabrutinib initiation
Seema A. Bhat et al.
BLOOD (2022)
Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
Nadine Kutsch et al.
HEMASPHERE (2022)
Bendamustine followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia: primary endpoint analysis of a multicenter, open-label, phase II trial (CLL2-BIO)
Paula Cramer et al.
HAEMATOLOGICA (2021)
Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience
Katharine L. Lewis et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Chronic lymohocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B. Eichhorst et al.
ANNALS OF ONCOLOGY (2021)
Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia
Carsten U. Niemann et al.
BLOOD (2021)
Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma
Yoshitaka Narita et al.
NEURO-ONCOLOGY (2021)
Zanubrutinib monotherapy for patients with treatment-naive chronic lymphocytic leukemia and 17p deletion
Constantine S. Tam et al.
HAEMATOLOGICA (2021)
Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenstrom Macroglobulinemia
Steven P. Treon et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Kinase inhibition in autoimmunity and inflammation
Ali A. Zarrin et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Ibrutinib's off-target mechanism: cause for dose optimization
Sara M. Zimmerman et al.
CANCER BIOLOGY & THERAPY (2021)
Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL
Wyndham H. Wilson et al.
CANCER CELL (2021)
Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non-Hodgkin Lymphoma
Marcelo Lima Ribeiro et al.
CLINICAL CANCER RESEARCH (2021)
The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma
Haoran Wang et al.
HEMATOLOGICAL ONCOLOGY (2021)
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study
Michael Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial
Anne-Sophie Michallet et al.
BLOOD (2021)
Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial
Steven Le Gouill et al.
BLOOD (2021)
Orelabrutinib: First Approval
Sohita Dhillon
DRUGS (2021)
Fenebrutinib in H-1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial
Martin Metz et al.
NATURE MEDICINE (2021)
Rituximab-Lenalidomide-Ibrutinib Combination for Relapsed/Refractory Primary CNS Lymphoma A Case Series of the LOC Network
Caroline Houillier et al.
NEUROLOGY (2021)
Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease
Claire L. Langrish et al.
JOURNAL OF IMMUNOLOGY (2021)
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
Anthony R Mato et al.
LANCET (2021)
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial
Jeff P. Sharman et al.
LANCET HAEMATOLOGY (2021)
Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease
Philipp von Hundelshausen et al.
CANCERS (2021)
Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects
H. Yesid Estupinan et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Acalabrutinib in treatment-naive chronic lymphocytic leukemia
John C. Byrd et al.
BLOOD (2021)
Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study
D. F. Murrell et al.
BRITISH JOURNAL OF DERMATOLOGY (2021)
Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial
Martin Kaul et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2021)
Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures
Garth E. Ringheim et al.
FRONTIERS IN IMMUNOLOGY (2021)
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial
Jacob D Soumerai et al.
Lancet Haematology (2021)
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia
Kerry A. Rogers et al.
HAEMATOLOGICA (2021)
Current and future treatment strategies in chronic lymphocytic leukemia
Krish Patel et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations
Nitin Jain et al.
LEUKEMIA (2021)
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies
Richard R. Furman et al.
LEUKEMIA (2021)
Phase I, first-in-human trial of Bruton's tyrosine kinase inhibitor M7583 in patients with B-cell malignancies
Wojciech Jurczak et al.
LEUKEMIA & LYMPHOMA (2021)
Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma*
Wyndham H. Wilson et al.
LEUKEMIA & LYMPHOMA (2021)
Ibrutinib combinations in CLL therapy: scientific rationale and clinical results
Natalia Timofeeva et al.
BLOOD CANCER JOURNAL (2021)
Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenstrom macroglobulinemia
Steven P. Treon et al.
BLOOD (2021)
Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies
Deborah M. Stephens et al.
BLOOD (2021)
BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL
Maissa Mhibik et al.
BLOOD (2021)
MOG autoantibodies trigger a tightly-controlled FcR and BTK-driven microglia proliferative response
Kathryn Pellerin et al.
BRAIN (2021)
The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma
Stephen Opat et al.
CLINICAL CANCER RESEARCH (2021)
A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenstrom Macroglobulinemia
Gang An et al.
CLINICAL CANCER RESEARCH (2021)
Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study
Paolo Strati et al.
HAEMATOLOGICA (2021)
Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19
Satyavani Kaliamurthi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
John C. Byrd et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
A multicenter, open-label, uncontrolled, single-arm phase 2 study of tirabrutinib, an oral Bruton's tyrosine kinase inhibitor, in pemphigus
Jun Yamagami et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2021)
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial
Daniel S. Reich et al.
LANCET NEUROLOGY (2021)
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm,-label, 2
Matthew S. Davids et al.
LANCET ONCOLOGY (2021)
Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial
David Isenberg et al.
ARTHRITIS & RHEUMATOLOGY (2021)
Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia A Nonrandomized Phase 2 Trial
Nitin Jain et al.
JAMA ONCOLOGY (2021)
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
William G. Wierda et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Next-generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cells
Eris Bame et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2021)
Current and novel BTK inhibitors in Waldenstrom's macroglobulinemia
Ioannis Ntanasis-Stathopoulos et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2021)
Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances
Tingyu Wen et al.
LEUKEMIA (2021)
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia
Fary Diop et al.
HAEMATOLOGICA (2020)
Ibrutinib induces multiple functional defects in the neutrophil response against Aspergillus fumigatus
Damien Blez et al.
HAEMATOLOGICA (2020)
Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma
Alex F. Herrera et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Epidemiology, clinical presentation, and pathogenesis
Samantha R. Goldburg et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
Jan A. Burger et al.
LEUKEMIA (2020)
Follicular lymphoma: 2020 update on diagnosis and management
Arnold Freedman et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results
John C. Byrd et al.
BLOOD (2020)
Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors
Paolo Strati et al.
BLOOD (2020)
A phase I study of carfilzomib in combination with ibrutinib for relapsed refractory mantle cell lymphoma
Hun J. Lee et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
Roman Hajek et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2020)
Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma
Ajai Chari et al.
HEMATOLOGICAL ONCOLOGY (2020)
Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia
Ola A. Elgamal et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase
Daniela Angst et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Acalabrutinib plus Obinutuzumab in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia
Jennifer A. Woyach et al.
CANCER DISCOVERY (2020)
A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis
Sang Eun Yoon et al.
ANNALS OF HEMATOLOGY (2020)
Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition
Albert Liclican et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2020)
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib
Clare Sun et al.
BLOOD (2020)
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients
Steven P. Treon et al.
BLOOD (2020)
Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS-986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo-controlled trial in healthy participants
Ian M. Catlett et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)
The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma
Nathan H. Fowler et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19
Santiago Thibaud et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia
Alexey V. Danilov et al.
CLINICAL CANCER RESEARCH (2020)
Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase
Yuqin Song et al.
CLINICAL CANCER RESEARCH (2020)
Acalabrutinib monotherapy in patients with Waldenstrom macroglobulinemia: a single-arm, multicentre, phase 2 study
Roger G. Owen et al.
LANCET HAEMATOLOGY (2020)
Bruton's tyrosine kinase in systemic lupus erythematosus
Hsien-Tzung Liao et al.
JOINT BONE SPINE (2020)
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Paolo Ghia et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study
Wei Xu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
A Fast and Clean BTK Inhibitor
Ronen Gabizon et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial
Jeff P Sharman et al.
LANCET (2020)
Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, PhaseIITrial
Stanley Cohen et al.
ARTHRITIS & RHEUMATOLOGY (2020)
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study
Constantine S. Tam et al.
BLOOD (2020)
Zanubrutinib for the treatment of patients with Waldenstrom macroglobulinemia: 3 years of follow-up
Judith Trotman et al.
BLOOD (2020)
Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma
David A. Bond et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2020)
A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenstrom's macroglobulinemia
Naohiro Sekiguchi et al.
CANCER SCIENCE (2020)
Inhibition of Bruton tyrosine kinase in patients with severe COVID-19
Mark Roschewski et al.
SCIENCE IMMUNOLOGY (2020)
Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases
Bin Ma et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia
Christopher Pleyer et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Salivary gland epithelial cells from patients with Sjogren's syndrome induce B-lymphocyte survival and activation
Elodie Riviere et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Graeme A. M. Fraser et al.
LEUKEMIA & LYMPHOMA (2020)
Waldenström Macroglobulinemia – 2020 Update on Management and Future Directions
Sheeba K. Thomas
Clinical Lymphoma Myeloma & Leukemia (2020)
Selective inhibition of thromboinflammation in COVID-19 by Btk inhibitors
Wolfgang Siess et al.
PLATELETS (2020)
Open trial of Bruton's tyrosine kinase inhibitor (PRN1008) in the treatment of canine pemphigus foliaceus
Elizabeth C. Goodale et al.
VETERINARY DERMATOLOGY (2020)
Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use
Feili Chen et al.
CANCER MEDICINE (2020)
Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma
Constantine S. Tam et al.
BLOOD ADVANCES (2020)
Recent advances in understanding pathogenesis and therapeutic strategies of Systemic Lupus Erythematosus
Shuaihantian Luo et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis
Ariela Noy et al.
BLOOD ADVANCES (2020)
Zanubrutinib for the treatment of MYD88 wild-type Waldenstrom macroglobulinemia: a substudy of the phase 3 ASPEN trial
Meletios Dimopoulos et al.
BLOOD ADVANCES (2020)
Pooled Analysis of Safety Data from Clinical Trials of Orelabrutinib Monotherapy in Hematologic Malignancies
Yuqin Song et al.
BLOOD (2020)
Long-Term Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study
Yuqin Song et al.
BLOOD (2020)
In Vivo Pre-Clinical Evaluation of LOXO-305 Alone and in Combination with Venetoclax, Rituximab, R-CHOP or Obinutuzumab on Human Xenograft Lymphoma Tumor Models in Mice
Eliana B. Gomez et al.
BLOOD (2020)
Nx-2127, a Degrader of BTK and IMiD Neosubstrates, for the Treatment of B-Cell Malignancies
Daniel W. Robbins et al.
BLOOD (2020)
Updated Results from the Phase II Study of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia
Wei Xu et al.
BLOOD (2020)
Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study
William G. Wierda et al.
BLOOD (2020)
Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study
Peter H. Schafer et al.
RHEUMATOLOGY AND THERAPY (2020)
ABBV-105, a selective and irreversible inhibitor of Bruton's tyrosine kinase, is efficacious in multiple preclinical models of inflammation
Christian Goess et al.
MODERN RHEUMATOLOGY (2019)
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab
John C. Byrd et al.
BLOOD (2019)
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma
Peter Martin et al.
BLOOD (2019)
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK)
Scott H. Watterson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial
Loretta J. Nastoupil et al.
LANCET HAEMATOLOGY (2019)
De-Cell-eration in Therapy for Diffuse Large B-Cell Lymphoma
John P. Leonard
JOURNAL OF CLINICAL ONCOLOGY (2019)
Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies
Kerry A. Rogers et al.
LEUKEMIA (2019)
Ibrutinib and Venetoclax for First-Line Treatment of CLL
Nitin Jain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis
Xavier Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL
Andre Goy et al.
BLOOD (2019)
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
Constantine S. Tam et al.
BLOOD (2019)
Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
Peter Hillmen et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton's Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis
Xia Yao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Absence of Pharmacokinetic Interactions between the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib and Methotrexate
Nicholas Steven Jones et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
T. D. Shanafelt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial
Anne-Sophie Michallet et al.
LANCET HAEMATOLOGY (2019)
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
Talha Munir et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
How we manage Bing-Neel syndrome
Jorge J. Castillo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network
C. Soussain et al.
EUROPEAN JOURNAL OF CANCER (2019)
Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases
Richard D. Caldwell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma
Michael Wang et al.
LEUKEMIA (2019)
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial
Matthew S. Davids et al.
LANCET HAEMATOLOGY (2019)
Safety, Tolerability and Efficacy of Orelabrutinib, Once a Day, to Treat Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia
Wei Xu et al.
BLOOD (2019)
Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies
Jennifer Woyach et al.
BLOOD (2019)
Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma
Christian Grommes et al.
BLOOD (2019)
Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study
Jorge J. Castillo et al.
BLOOD (2019)
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia
Jan A. Burger et al.
BLOOD (2019)
Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study
Yuqin Song et al.
BLOOD (2019)
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
Carol Moreno et al.
LANCET ONCOLOGY (2019)
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
G. Fraser et al.
LEUKEMIA (2019)
Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia
Alexander P. de Porto et al.
MOLECULAR MEDICINE (2019)
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study
Matthew S. Davids et al.
LANCET HAEMATOLOGY (2019)
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study
Anas Younes et al.
LANCET HAEMATOLOGY (2019)
Bruton's tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption
Yuko Ariza et al.
BONE REPORTS (2019)
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib
Farrukh T. Awan et al.
BLOOD ADVANCES (2019)
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL
J. R. Brown et al.
LEUKEMIA (2018)
Inhibiting Bruton's tyrosine kinase rescues mice from lethal influenza-induced acute lung injury
Jon M. Florence et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2018)
Bruton's tyrosine kinase regulates TLR7/8-induced TNF transcription via nuclear factor-κB recruitment
Theresa H. Page et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL
Craig S. Sauter et al.
BLOOD (2018)
Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL
Sean D. Reiff et al.
BLOOD (2018)
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
Michael Hallek et al.
BLOOD (2018)
Single-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
Susan O'Brien et al.
BLOOD (2018)
Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation in humans
Kristina Busygina et al.
BLOOD (2018)
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocyticleukaemia treated with ibrutinib from 3 clinical trials
Jeffrey Jones et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results
Paul G. Richardson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL)
Preetesh Jain et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma
Kieron Dunleavy et al.
CANCER TREATMENT REVIEWS (2018)
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2
Paul M. Barr et al.
HAEMATOLOGICA (2018)
Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenstrom macroglobulinemia
Jorge J. Castillo et al.
HAEMATOLOGICA (2018)
Pemphigus group: overview, epidemiology, mortality, and comorbidities
Khalaf Kridin
IMMUNOLOGIC RESEARCH (2018)
Disrupting the Btk Pathway Suppresses COPD-Like Lung Alterations in Atherosclerosis Prone ApoE-/- Mice Following Regular Exposure to Cigarette Smoke
Jon M. Florence et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study
Ajay K. Gopal et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development
James J. y Crawford et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Acalabrutinib in mantle cell lymphoma
Prashant Kapoor et al.
LANCET (2018)
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
Michael Wang et al.
LANCET (2018)
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial
Jeffrey A. Jones et al.
LANCET ONCOLOGY (2018)
Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma
Ajai Chari et al.
LEUKEMIA & LYMPHOMA (2018)
Role of Bruton's tyrosine kinase in B cells and malignancies
Simar Pal Singh et al.
MOLECULAR CANCER (2018)
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom's Macroglobulinemia
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
Constantine S. Tam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2
Paul M. Barr et al.
HAEMATOLOGICA (2018)
Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenstrom macroglobulinemia
Jorge J. Castillo et al.
HAEMATOLOGICA (2018)
Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study
Xiaojun Huang et al.
CANCER MEDICINE (2018)
Targeting B Cells and Plasma Cells in Autoimmune Diseases
Katharina Hofmann et al.
FRONTIERS IN IMMUNOLOGY (2018)
Bruton's Tyrosine Kinase, a Component of B Cell Signaling Pathways, Has Multiple Roles in the Pathogenesis of Lupus
Anne B. Satterthwaite
FRONTIERS IN IMMUNOLOGY (2018)
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial
Mats Jerkeman et al.
LANCET HAEMATOLOGY (2018)
LOXO-305, A Next Generation Reversible BTK Inhibitor, for Overcoming Acquired Resistance to Irreversible BTK Inhibitors
Barbara Brandhuber et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Ibrutinib Monotherapy in Symptomatic, Treatment-Naive Patients With Waldenstrom Macroglobulinemia
Steven P. Treon et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation
Sean D. Reiff et al.
CANCER DISCOVERY (2018)
BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis
Samantha A. Chalmers et al.
CLINICAL IMMUNOLOGY (2018)
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
J. A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Effect of the BTK inhibitor ibrutinib on macrophage- and γδ T cell-mediated response against Mycobacterium tuberculosis
Ana Colado et al.
BLOOD CANCER JOURNAL (2018)
A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL
Chaitra Ujjani et al.
BLOOD ADVANCES (2018)
Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia
Kerry A. Rogers et al.
BLOOD (2018)
Targeting B cell receptor signalling in cancer: preclinical and clinical advances
Jan A. Burger et al.
NATURE REVIEWS CANCER (2018)
Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial
Nancy L. Bartlett et al.
BLOOD (2018)
Highly selective inhibition of Bruton's tyrosine kinase attenuates skin and brain disease in murine lupus
Samantha A. Chalmers et al.
ARTHRITIS RESEARCH & THERAPY (2018)
Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial
Jeff P. Sharman et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia
Sarah E. M. Herman et al.
CLINICAL CANCER RESEARCH (2017)
Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib
J. Yu et al.
LEUKEMIA (2017)
Ibrutinib treatment improves T cell number and function in CLL patients
Meixiao Long et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Ibrutinib for patients with rituximab-refractory Waldenstrm's macro globulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial
Meletios A. Dimopoulos et al.
LANCET ONCOLOGY (2017)
Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care
Kathleen M. Gillooly et al.
PLOS ONE (2017)
Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma
Xiaohong Zhao et al.
NATURE COMMUNICATIONS (2017)
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma
Michail S. Lionakis et al.
CANCER CELL (2017)
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL
Paul M. Barr et al.
BLOOD (2017)
Acquired mutations associated with ibrutinib resistance in Waldenstrom macroglobulinemia
Lian Xu et al.
BLOOD (2017)
Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients
A. R. Mato et al.
ANNALS OF ONCOLOGY (2017)
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma
Ariela Noy et al.
BLOOD (2017)
A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies
Harriet S. Walter et al.
BLOOD (2016)
Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib - Findings from an Investigator-Initiated Phase II Study
Carsten U. Niemann et al.
CLINICAL CANCER RESEARCH (2016)
HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma
Caron Jacobson et al.
BLOOD (2016)
Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103
Chaitra S. Ujjani et al.
BLOOD (2016)
Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma
Nakhle S. Saba et al.
BLOOD (2016)
HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib
Guang Yang et al.
BLOOD (2016)
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
Joseph A. Fraietta et al.
BLOOD (2016)
Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib
Inhye E. Ahn et al.
BLOOD (2016)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma
Dai Maruyama et al.
CANCER SCIENCE (2016)
Btk inhibition treats TLR7/IFN driven murine lupus
Andrew T. Bender et al.
CLINICAL IMMUNOLOGY (2016)
Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia
Jennifer R. Brown et al.
HAEMATOLOGICA (2016)
Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers
Scott H. Watterson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study
Martin Dreyling et al.
LANCET (2016)
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study
Susan O'Brien et al.
LANCET ONCOLOGY (2016)
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study
Asher Chanan-Khan et al.
LANCET ONCOLOGY (2016)
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia
Jennifer R. Brown et al.
HAEMATOLOGICA (2016)
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study
Samantha M. Jaglowski et al.
BLOOD (2015)
The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia
Jennifer R. Brown et al.
BLOOD (2015)
Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation
Ta-Ming Liu et al.
BLOOD (2015)
Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib
Clare Sun et al.
BLOOD (2015)
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
Michael L. Wang et al.
BLOOD (2015)
Bruton Tyrosine Kinase Is a Therapeutic Target in Stem-like Cells from Multiple Myeloma
Ye Yang et al.
CANCER RESEARCH (2015)
Phagocytosis-dependent activation of a TLR9-BTK-calcineurin-NFAT pathway co-ordinates innate immunity to Aspergillus fumigatus
Susanne Herbst et al.
EMBO MOLECULAR MEDICINE (2015)
Role of Bruton's tyrosine kinase inhibitors in HIV-1-infected cells
Irene Guendel et al.
JOURNAL OF NEUROVIROLOGY (2015)
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial
Mohammed Z. H. Farooqui et al.
LANCET ONCOLOGY (2015)
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wyndham H. Wilson et al.
NATURE MEDICINE (2015)
Ibrutinib in Previously Treated Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens
Ryan M. Young et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma
Kami Maddocks et al.
BLOOD (2015)
Dynamics of B cells in germinal centres
Nilushi S. De Silva et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)
Jennifer A. Woyach et al.
BLOOD (2014)
Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib
Dominik Wodarz et al.
BLOOD (2014)
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
Susan O'Brien et al.
LANCET ONCOLOGY (2014)
Pharmacological and genomic profiling identifies NF-kappa B-targeted treatment strategies for mantle cell lymphoma
Rami Rahal et al.
NATURE MEDICINE (2014)
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ibrutinib Resistance in Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Targeting Bruton's tyrosine kinase in B cell malignancies
Rudi W. Hendriks et al.
NATURE REVIEWS CANCER (2014)
Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients
Betty Y. Chang et al.
BLOOD (2013)
Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
Qingsong Liu et al.
CHEMISTRY & BIOLOGY (2013)
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
Ranjana H. Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Selective Inhibition of BTK Prevents Murine Lupus and Antibody-Mediated Glomerulonephritis
Andrew L. Rankin et al.
JOURNAL OF IMMUNOLOGY (2013)
Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis
Munevver Cinar et al.
LEUKEMIA RESEARCH (2013)
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Bruton's Tyrosine Kinase Mediates the Synergistic Signalling between TLR9 and the B Cell Receptor by Regulating Calcium and Calmodulin
Elaine F. Kenny et al.
PLOS ONE (2013)
Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans
Erica K. Evans et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
Martin F. M. de Rooij et al.
BLOOD (2012)
Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice
Laurens P. Kil et al.
BLOOD (2012)
BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas
Qingguo Yan et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Molecular pathogenesis of mantle cell lymphoma
Pedro Jares et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling
Marcus Duehren-von Minden et al.
NATURE (2012)
Bruton's tyrosine kinase phosphorylates Toll-like receptor 3 to initiate antiviral response
Koon-Guan Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
Sarah E. M. Herman et al.
BLOOD (2011)
The B-cell antigen receptor signals through a preformed transducer module of SLP65 and CIN85
Thomas Oellerich et al.
EMBO JOURNAL (2011)
Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis
Julie A. Di Paolo et al.
NATURE CHEMICAL BIOLOGY (2011)
Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling
Chiara Pighi et al.
CELLULAR ONCOLOGY (2011)
Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin
Charles C. Chu et al.
BLOOD (2010)
The Src, Syk, and Tec family kinases: Distinct types of molecular switches
J. Michael Bradshaw
CELLULAR SIGNALLING (2010)
Genes on the X chromosome affect development of collagen-induced arthritis in mice
L. JANSSON et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
R. Eric Davis et al.
NATURE (2010)
Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain
Abdalla J. Mohamed et al.
IMMUNOLOGICAL REVIEWS (2009)
Protein Profiling of Plasma Membranes Defines Aberrant Signaling Pathways in Mantle Cell Lymphoma
Robert S. Boyd et al.
MOLECULAR & CELLULAR PROTEOMICS (2009)
Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma
Mara Compagno et al.
NATURE (2009)
Fine-tuning of GPCR activity by receptor-interacting proteins
Stefanie L. Ritter et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2009)
Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals
Masahiro Shinohara et al.
CELL (2008)
Phospholipase C-γ2 and Vav cooperate within signaling microclusters to propagate B cell spreading in response to membrane-bound antigen
Michele Weber et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Chronic Lymphocytic Leukemia Cells Recognize Conserved Epitopes Associated with Apoptosis and Oxidation
Rosa Catera et al.
MOLECULAR MEDICINE (2008)
Stromal Gene Signatures in Large-B-Cell Lymphomas
G. Lenz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma
Georg Lenz et al.
SCIENCE (2008)
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Teru Hideshima et al.
NATURE REVIEWS CANCER (2007)
Bruton's tyrosine kinase and phospholipase C gamma 2 mediate chemokine-controlled B cell migration and homing
David J. J. de Gorter et al.
IMMUNITY (2007)
Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo
Junling Liu et al.
BLOOD (2006)
Mechanism of B-cell receptor-induced phosphorylation and activation of phospholipase C-γ2
YJ Kim et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
IVIg-mediated amelioration of murine ITP via FcγRIIB is independent of SHIP1, SHP-1, and Btk activity
AR Crow et al.
BLOOD (2003)
Bruton's tyrosine kinase is a toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor κB activation by toll-like receptor 4
CA Jefferies et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Amplification of B cell antigen receptor signaling by a Syk/ITAM positive feedback loop
V Rolli et al.
MOLECULAR CELL (2002)
Vav3 modulates B cell receptor responses by regulating phosphoinositide 3-kinase activation
K Inabe et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
G protein βγ subunits act on the catalytic domain to stimulate Bruton's agammaglobulinemia tyrosine kinase
WE Lowry et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells
RE Davis et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
BCAP: The tyrosine kinase substrate that connects B cell receptor to phosphoinositide 3-kinase activation
T Okada et al.
IMMUNITY (2000)
Defects in early B-cell development: comparing the consequences of abnormalities in pre-BCR signaling in the human and the mouse
ME Conley et al.
IMMUNOLOGICAL REVIEWS (2000)
Share Paper
